PACE is the first phase 3 randomized trial directly comparing radical prostatectomy with SBRT in men with low- to intermediate-risk prostate cancer.

Dr Rena Malik is a board-certified urologist, pelvic surgeon, and sexual health expert whose social media channels educate millions of subscribers. Dr Rena Malik is a board-certified urologist, pelvic ...

Findings seen in adults aged 40 to 80 years with at least two cardiovascular risk factors. (HealthDay News) — For adults with an increased cardiovascular risk, elevated C-reactive protein (CRP) levels ...

Degevma (denosumab-adet) has received FDA approval as a biosimilar to Xgeva, demonstrating bioequivalence in safety, efficacy, and immunogenicity. The Food and Drug Administration (FDA) has approved ...

The effects of semaglutide on major adverse cardiovascular events (MACE) is only partially due to known risk factors, according to a study published online Sept. 23 in the European Heart Journal.

Trial investigators evaluated the prognostic and predictive ability of PAM50 molecular prostate cancer subtypes to guide salvage treatment.

The pre-formed and radiopaque flex hydrogel spacer is now FDA approved and will begin limited distribution in the US. The US Food and Drug Administration (FDA) has granted 510 (k) clearance for ...

Adding lactoferrin to oral liposomal iron improved hemoglobin levels, transferrin saturation, and serum iron compared with oral iron alone in chronic kidney disease with or without dialysis. Adding ...

Men with frailty have higher risk for cognitive impairment than men without frailty, but no association seen in women.

Although cannabis and CBD can offer modest symptom relief for chronic pain, health care providers should counsel patients on outcomes and drug interactions before use. For health care providers who ...